Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Operating expenses    
Research and development $ 311,302 $ 939,040
General and administrative 3,547,927 3,531,540
Total operating expenses 3,859,229 4,470,580
Operating loss (3,859,229) (4,470,580)
Interest expense 667  
Other expense (income)    
Change in fair value of warrant liability (560,986) (1,342,651)
Change in fair value of conversion rights of Series B preferred stock (102,848) 48,564
Change in fair value of put option value of Series F preferred stock (103,364)  
Net Loss before income taxes (3,092,698) (3,176,493)
Provision for income taxes 1,600 1,600
Net loss (3,094,298) (3,178,093)
Less: Preferred deemed dividend 1,044,000 325,000
Net loss applicable to common shareholders $ (4,138,298) $ (3,503,093)
Basic earnings per common share (in dollars per share) $ (0.11) $ (0.17)
Diluted earnings per common share (in dollars per share) $ (0.11) $ (0.17)
Weighted average shares of common stock outstanding    
Basic (in shares) 27,906,090 18,947,375
Diluted (in shares) 27,906,090 18,947,375